Amino, Yoshiaki
Kitazono, Satoru
Uematsu, Shinya
Hasegawa, Tsukasa
Yoshizawa, Takahiro
Uchibori, Ken
Yanagitani, Noriko
Horiike, Atsushi
Horai, Takeshi
Kasahara, Kazuo
Nishio, Makoto
Article History
Received: 10 April 2019
Accepted: 28 August 2019
First Online: 10 September 2019
Compliance with ethical standards
:
: All the authors approved the submission this manuscript to your journal. Makoto Nishio reports honoraria from Ono, BMS, Pfizer, Chugai,Taiho Pharmac, AstraZeneca, Boehringer-ingelheim, MSD, and Novartis, research funding from Novartis, Daiichi Sankyo, Taiho Pharma, BMS, Boehringer-ingelheim, Ono Phrmaceutical, Eli Lilly, Chugai, AstraZeneca, Merck Sernon, MSD and Pfizer. Noriko Yanagitani reports employment/ledership position/ advisory role of Chugai Phrmaceutical. Atsushi Horiike reports horaria from chugai pharma, AstraZeneca, Pfizer, Ono Phrmaceutical, Bristol-Myers Squibb Japan, A2 Healthcare and MSD oncology, research funding from Chugai Pharma, MSD Oncology, Abbvie, AstraZeneca and Loxo. We agree to allow the journal to review our data if requested.